MedTrace Logo

Use of Cefiderocol in the Management of Gram-Negative Infections

NCT05789199 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 314

Last updated 2023-06-26

No results posted yet for this study

Summary

The aim of this study is to describe the use of cefiderocol in the management of Gram-negative infections (GNIs) in participants treated through the Early Access Program (EAP) in Spain.

Conditions

  • Gram-Negative Infection

Interventions

DRUG

Cefiderocol

Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2023-06-16
Completion
2023-06-16
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05789199 on ClinicalTrials.gov